Oncolytics Biotech (TSE:ONC) Sets New 52-Week Low – Here’s Why

Oncolytics Biotech Inc. (TSE:ONC) shares reached a new 52-week low during trading on Monday . The company traded as low as C$0.98 and last traded at C$1.00, with a volume of 139671 shares traded. The stock had previously closed at C$1.07.

Wall Street Analyst Weigh In

Separately, Raymond James raised shares of Oncolytics Biotech to a “moderate buy” rating in a report on Thursday, November 14th.

Oncolytics Biotech Trading Down 5.6 %

The firm has a market capitalization of C$77.63 million, a P/E ratio of -2.66 and a beta of 1.35. The company has a debt-to-equity ratio of 6.09, a quick ratio of 8.86 and a current ratio of 4.99. The firm has a 50 day moving average price of C$1.24 and a two-hundred day moving average price of C$1.37.

Oncolytics Biotech (TSE:ONC) last released its earnings results on Tuesday, November 12th. The company reported C($0.12) earnings per share for the quarter, missing the consensus estimate of C($0.11) by C($0.01). During the same period last year, the firm earned ($0.14) EPS. On average, equities research analysts expect that Oncolytics Biotech Inc. will post -0.41 EPS for the current fiscal year.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.